Zuclopenthixol dihydrochloride for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Kumar, Ajit ^a   Strech, Daniel ^b  

^a LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antipsychotic agents adverse effects; *therapeutic use ; Clopenthixol adverse effects; *therapeutic use ; Humans; Movement disorders etiology ; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOPENTHIXOL; CLOPIXOL ACUTARD; CLOTIAPINE; CLOZAPINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TEMAZEPAM; TIOTIXENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE;

AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; CONFUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPOKINESIA; HYPOMANIA; MENTAL HEALTH; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PARANOID SCHIZOPHRENIA; PATIENT SATISFACTION; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RIGOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; STIMULATION; SYMPTOM; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 77950134171     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005474     Document Type: Review

References (113)

1. Aaes-Jorgensen 1981b {published data only} * Aaes-Jorgensen T, Gravem A, Jorgensen A. Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis (Z)-trans(E)- clopenthixol. Acta Psychiatrica Scandinavica Supplementum 1981;294:70-7. [MEDLINE: 82178887; : PMID 6951396]
2. Balasubramanian 1991 {published data only} Balasubramanian K, Baloch N, Briscoe MH, Chattree S, Cooper CJ, Durani SK, Judge R, Gunawardena VR, Mahadevan K Mann, BS Pandita, Patel AG, Saleem PT, Sekhawat BS, Suri AK. A double blind multicentre comparison of oral zuclopenthixol and oral chlorpromazine in the treatment of acute psychosis. British Journal of Clinical Research 1991;n/a:149-56. [MEDLINE: 69006168; : PMID 5600894]
3. Ban 1975 {published data only} Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36(9):473-7. [MEDLINE: 76021805; : PMID 240651] Lehmann HE, Ban TA. Thiothixene versus chlorprothixene versus clopenthixol. Psychopharmacology Bulletin 1970;6(4):112-5. [: 13027]
4. Dehnel 1968 {published data only} Dehnel LL, Vestre ND, Schiele BC. A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Current Therapeutic Research Clinical and Experimental 1968;10:169-76. [MEDLINE: 68242121; : PMID 4967871]
5. Fischer 1976 {published data only} Fischer-Cornelssen KA, Ferner UJ. An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacology Bulletin 1976;12:34-9.
6. Galderisi 1994 {published data only} Galderisi S, Maj M, Mucci A, Bucci P, Kemali D. QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry 1994;35(6):367-74. [MEDLINE: 94289546; : EMBASE 1994114037; PMID 8018782]
7. Gravem 1978 {published data only} * Gravem A, Engstrand E, Guleng RJ. Cis(Z)-clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. A doubleblind clinical investigation.. Acta Psychiatrica Scandinavica 1978;58 (5):384-8. [MEDLINE: 79058923; : PMID 362830]
8. Gravem 1981 {published data only} Gravem A, Bugge A. Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. A double-blind clinical investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:13-24. [MEDLINE: 82178878; : PMID 7041515]
9. Heikkila 1981a {published data only} Heikkila L, Karsten D, Valli K. A double-blind clinical investigation of cis(Z)-clopenthixol and clopenthixol in chronic schizophrenic patients. Acta Psychiatrica Scandinavica Supplementum 1981;294: 25-9. [MEDLINE: 82178880; : PMID 7041516]
10. Heikkila 1981b {published data only} Heikkila L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:30-8. [MEDLINE: 82178881; : PMID 7041517]
11. Heikkila 1992 {published data only} * Heikkila L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multicentre study. Current Medical Research and Opinion 1992;12(9):594-603. [: EMBASE 1992128093]
12. Huttunen 1995 {published data only} Huttunen MO, Piepponen T. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes. European Psychiatry 1994;9(Suppl 1):85.
13. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.. Acta Psychiatrica Scandinavica 1995;91(4):271-7.
14. Moller HJ, Huttunen MO. The prevalence of extrapyramidal symptoms during short and long term treatment with risperidone. 7th Biennial European Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland 1994;11(2):106. [MEDLINE: 94001724; : PMID 8104468]
15. Kingstone 1970 {published data only} Kingstone E, Kolivakis T, Kossatz I. Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1970;3(1):41-5. [MEDLINE: 70164847; : PMID 4909377]
16. Kordas 1968 {published data only} Kordas SK, Kazamias NG, Georgas JG, Papadokostakis JG. Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients. British Journal of Psychiatry 1968;114(512): 833-6. [MEDLINE: 68329665; : PMID 4874163]
17. Mahadevan 1991 {published data only} Mahadevan K, Gadhvi HM, Suri AK, Hussain MF, Sharma VK, Sharma SK, Palia SS, Mukherjee PK, Chan Pensley E, Ghoshal J, Ahmed W, Bhatt GS. A multicentre comparison of oral zuclopenthixol dihydrochloride and oral sulpiride in the treatment of acute schizophrenia. British Journal of Clinical Research 1991;2: 13-20. [: Cochrane Library CN-00282616]
18. Remvig 1987 {published data only} Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Stromgren LS. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study. Pharmacopsychiatry 1987; 20(4):147-54. [MEDLINE: 87290070; : PMID 3615572]
19. Serafetinides 1972 {published data only} Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8(4):214-6. [MEDLINE: 74083340; : PsycINFO 52-05954; PMID 4589640]
20. Serafetinides E A. Voltage laterality in the EEG of psychiatric patients.. Diseases of the Nervous System. 1973;34(3):190-1. [MEDLINE: 73210072; : PsycINFO 1973-29665-001; PMID 4715636]
21. Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7(3):263-7. [MEDLINE: 74051947; : PsycINFO 52-03694; PMID 4586833]
22. * Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease 1972;154(1):31-42. [MEDLINE: 72081124; : PMID 4550211]
23. Serafetinides E A, Willis D. A method of quantifying EEG for psychopharmacological research.. International Pharmacopsychiatry. 1973;8(4):245-7.
24. Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Journal of Nervous and Mental Disease 1972;155(5):366-9. [MEDLINE: 73029970; : PMID 4563078]
25. Sterlin 1972 {published data only} Sterlin C, Ban TA, Jarrold L. The place of thiothixene among the thioxanthenes. Current Therapeutic Research Clinical and Experimental 1972;14(4):205-14. [MEDLINE: 72182264; : PMID 4623599]
26. Aaes-Jorgensen 1981a {published data only} Aaes-Jorgensen T. Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta Psychiatrica Scandinavica Supplementum 1981;294:64-9. [MEDLINE: 82178886; : PMID 6951395]
27. Ahlfors 1980 {published data only} Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatrica Scandinavica Supplementum 1980;279:77-91. [MEDLINE: 80262296; : PMID 6996426]
28. Al Haddad 1996 {published data only} Al Haddad MK, Kamel C, Mawgood MA, Sequeria RP. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses,affective psychoses and paranoid states: a controlled clinical trial.. Arab Journal of Psychiatry 1996;7(1): 44-54. [: PsycINFO 2001-16512-004]
29. Arango 2002 {published data only} Arango C, Bomb́n I, Bobeś J, Gonzalez-, Cabeza Garća-, Salvador MT. Prediction and prevention of violence in schizophrenia outpatients: preliminary report. Schizophrenia Research 2002;53(3 Suppl.1):233. [MEDLINE: 2003183416]
30. Baastrup 1993 {published data only} Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-Andersen K. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica 1993;37(1):48-58. [MEDLINE: 93142586; : PMID 8093824]
31. Bereen 1987 {published data only} * Bereen FJ, Harte FB, Maguire J, Singh AN. The use of oral zuclopenthixol in the treatment of functional psychotic illness. Pharmatherapeutica 1987;5(1):61- 8.
32. Bhattacharya 1987 {published data only} Bhattacharya SN, Ghoshal J, Sharma SK, Halstead N, John B, Launer MA, Mukherjee PK, Zigmond AS. Acute functional psychoses:treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets. Pharmatherapeutica 1987;5(1):1-8.
33. Bobon 1989 {published data only} Bobon D, de Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study. 2nd Congress of the European College of Neuropsychopharmacology; 1989 May 24-26; Gothenburg, Germany. 1989. [MEDLINE: 76021805; : PMID 240651]
34. Bobon D, de Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study. New Strategies in the Treatment of Aggressive, Acutely Psychotic Patients. Proceedings of the 8th World Congress of Psychiatry; 1989 October 13-19, Athens, Greece. Excerpta Medica, 1989: 47-59. [MEDLINE: 76021805; : PMID 240651]
35. Bourdouxhe 1987 {published data only} Bourdouxhe S, Mirel J, DenysW, Bobon D. Zuclopenthixol acetate and haloperidol in acute psychoses - results of the AMDP subgroup of a Belgian multicenter study [L'acetate de zuclopenthixol et l'haloperidol dans la psychose aigue - Resultats du sous groupe AMDP d'une etude multicentrique belge]. Acta Psychiatrica Belgica 1987;87(2):236-44. [MEDLINE: 87295330; : PsycINFO 26-73137; PMID 3618274]
36. Brook 1996 {published data only} Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [MEDLINE: 95351128; : PMID 7542829]
37. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Unpublished Report submitted to Human Psychopharmacology Clinical and Experimental 1996. [MEDLINE: 95351128; : PMID 7542829]
38. * Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Human Psychopharmacology 1998;13(1):17-20. [: EMBASE 1998035700]
39. Burke 2002 {published data only} Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72:449-54.
40. Chin 1998 {published data only} Chin CN, Hamid AR, Philip G, Ramlee T, Mahmud M, Zulkifli G, Loh CC, Zakariah MS, Norhamidah MS, Suraya Y, Roslan KA, Chandramohan P, Cheah YC, Leonard AO. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia 1998;53(4):365-71. [MEDLINE: 74083340; : PsycINFO 52-05954; PMID 4589640]
41. Chouinard 1991 {published data only} Chouinard G, Safadi G, Beauclair L. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Journal of Clinical Psychopharmacology 1994;14(6): 377-84. [MEDLINE: 95190073; : PMID 7884017]
42. Chouinard G, Safadi G, Beauclair L. The management of acutely schizophrenic patients newly admitted from the emergency room: a double-blind clinical trial comparing zuclopenthixol acetate and liquid haloperidol. Modern Trends in the Treatment of Chronic Schizophrenia. Proceedings of a Symposium; 1991 June 10, Florence, Italy. Excerpta Medica, 1991:35-43. [MEDLINE: 95190073; : PMID 7884017]
43. Clark 1969 {published data only} Clark. Sordinol versus chlorpromazine versus placebo. Psychopharmacology Bulletin 1969;3:54-6. [: 01003]
44. Den 2000 {published data only} * Den Boer JA, Vahlne J O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. [: EMBASE 2000170004]
45. Dencker 1980 {published data only} Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatrica Scandinavica Supplementum 1980;279: 10-28. [MEDLINE: 80262290; : PMID 6931470]
46. Dencker SJ, Malm U, Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta Psychiatrica Scandinavica Supplementum 1980;279:55- 63. [MEDLINE: 80262294; : PMID 6931473]
47. Dom 1978 {published data only} Dom R, DeMesmaecker L, van den BrouckeM, van Hest T, Baro F. Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot. Acta Psychiatrica Scandinavica 1978;57 (4):299-304. [MEDLINE: 78207721; : PMID 352094]
48. Fagerlund 2003 {published data only} Fagerlund B, Mackeprang T, Gade A, Glenthoj BY. Effects of risperidone and zuclopenthixol on cognitive deficits in drug-naive first episode schizophrenic patients. Schizophrenia Research 2003; 60:133-4. [: CN-00394142]
49. Fensbo 1990 {published data only} Fensbo C. Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients - A controlled multicenter study. Meeting of the Scandinavian Society for Psychopharmacology (1989, Copenhagen, Denmark) [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift 1990;44(3): 295-7. [: PsycINFO 28-73892]
50. Glenthoj 2000 {published data only} Glenth¢j BY, Mackeprang T, Fagerlund B, Hemmingsen RP. Effects of antipsychotic treatment on prepulse inhibition of the startle response (ppi) and cognition in first episode drug-naive schizophrenic patients. Schizophrenia Research 2001;49(1,2):133. [: PsycINFO 2001-16512-004]
51. Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen R. Effects of antipsychotics on information-processing and extrastriatal dopamine d2/d3 receptors in first-episode drug-naive schizophrenic patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico. 2000:191. [MEDLINE: 95275743; : PMID 7756183]
52. Gravem 1990 {published data only} Gravem A, Elgen K. Cis(Z) clopenthixol. The neuroleptically active isomer of clopenthixol. A presentation of five double blind clinical investigations and other studies with cis(Z) clopenthixol (Cisordinol (R), Clopixol(R)). Acta Psychiatrica Scandinavica, Supplementum 1981;64(294):5-12. [MEDLINE: 82178884; : PMID 6122337]
53. * Gravem Arne, Tove AJ. Co-injection of zuclopenthixol acetate and zuclopenthixol decanoate. Nordisk Psykiatrisk Tidsskrift 1990; 44(4):403-5. [: PsycINFO 78-07960]
54. Hicklin 1967 {published data only} Hicklin A, Angst J. Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses [Retrospektive und prospektive Studie uber die klinische Wirkung von Clopenthixol (Sordinol) bei endogenen Psychosen]. Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine 1967;97(19):615-21. [MEDLINE: 69006168; : PMID 5600894]
55. Hovens 2003 {published data only} Hovens JEJM, Beijeman S, Tollenar J, Dries PJT, Loonen AJM. Risperidone versus zuclopenthixol in acute psychosis in emergency psychiatry: a prospective naturalistic study.. Journal of the European College of Neuropsychopharmacology. 2003;13(4):S293.
56. Huang 2001 {published data only} Huang SH, Pan YH, Wu FY, Qiu YP, et al.Comparison of clopenthixol decanoate to chlorpromazine in the treatment of schizophrenia. Chinese General Practice 2001;4(10): 775-6. [: CN-00393723]
57. Karsten 1981 {published data only} Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S. Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(Z)-clopenthixol and haloperidol. Acta Psychiatrica Scandinavica Supplementum 1981;294(64):39-45. [MEDLINE: 82178882; : PMID 7041518]
58. Knegtering 2002a {published data only} Knegtering H, Castelein S, Van Der Linde J, Bous J. Sexual dysfunctions and serum prolactin levels in patients using risperidone or quetiapine: a randomised trial. Schizophrenia Research 2002;53(3 Suppl 1):163.
59. Koskinen 1991 {published data only} Koskinen T, Wistedt B, Thelander S. Zuclopenthixol decanoate vs haloperidol decanoate: a double-blind comparative trial. 5th World Congress of Biological Psychiatry; 1991 Jun 9-14; Florence, Italy. 1991:563-5. [MEDLINE: 95275743; : PMID 7756183]
60. Kristiansen 2001 {published data only} Kristiansen KT, Mackeprang T, Fink-Jensen A, Hemmingsen RP, Glenth¢j BY. Effects of antipsychotics and other agents on prepulse inhibition of the starlte response(ppi). Schizophrenia Research 2001; 49(1,2):216. [: PsycINFO 2001-16512-004]
61. Loza 2001 {published data only} Loza B, Kucharska-Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey) 2001;11(3):285. [: 14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2103#]
62. Lublin 1991 {published data only} Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology 1991;1 (4):541-8. [: EMBASE 1998035700]
63. Mackeprang 2001 {published data only} Mackeprang T, Fagerlund B, Videbaek C, Hemmingsen RP, Glenthoj BY. Extrastriatal dopamine(d2/d3)-receptor occupancy and cognition in first episode schizophrenic patients.. Schizophrenia Research 2001;49(Suppl.1,2):194. [: LMD163341]
64. Malt 1995 {published data only} Malt UF, Nystad R, Bache T, Noren O, Sjaastad M, Solberg KO, Tonseth S, Zachariassen P, Maehlum E. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. British Journal of Psychiatry 1995;166(3):374-7. [MEDLINE: 95307869; : PMID 7788130]
65. Mann 1985 {published data only} Mann BS, Moslehuddin KS, Owen RT, Clayton AR, Rohatgi KK, Sud P, Vaddadi KS. A clinical assessment of zuclopenthixol dihydrochloride ('Clopixol Tablets') in the treatment of psychotic illness. Pharmatherapeutica 1985;4(6):386-392.
66. Martyns 1993 {published data only} Martyns Yellowe IS. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry. West African Journal of Medicine 1993;12(2):110-3. [MEDLINE: 94001724; : PMID 8104468]
67. Martyns-Yellowe IS. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West African Journal of Medicine 1994;13(4):200-3. [MEDLINE: 95275743; : PMID 7756183]
68. Mazurek 2003 {published data only} Mazurek I, Loza B, Lecyk A. Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. Journal of the European College of Neuropsychopharmacology 2003;13(4):S347. [: P.2.156]
69. Meyers 1972 {published data only} Meyers C, Lhoas JP, Huvelle R. Rediscovery of a neuroleptic drug in a new form: clopenthixol [Redecouverte d'un neuroleptique sous une autre presentation: le clopenthixol]. Schweizerische Rundschau fur Medizin Praxis 1972;61(26):869-71. [: Cochrane Library CN-00282616]
70. Mosolov 2000 {published data only} Mosolov SN, Molodetskikh AV, Eryomin AV, Graikov GM, Nourislamov SV. Effect and tolerability of Clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomized investigation. Sotsial'Naia I KlinIcheskaia Psikhiatria 2000;10(2):47-52. [MEDLINE: 68242121; : PMID 4967871]
71. Ropert 1988 {published data only} Ropert R, Hoepfner Petersen HE, Benyay J. Where zuclopenthixol acetate stands amid the 'modified release' neuroleptics [Place de l'acetate de zuclopenthixol au sein des neuroleptiques a liberation modifiee]. Congres de Psychiatrie et de Neurologie de Langue Francaise, LXXXVIth Session; 1988 Jun 13-17; Chambery, France. 1988:350-62. [MEDLINE: 87290070; : PMID 3615572]
72. Saxena 1996 {published data only} Saxena B. The value of depot neuroleptic injections in the treatment of chronic schizophrenia. Schizophrenia 1996 - Breaking down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver, Canada. 1996. [MEDLINE: 73210072; : PsycINFO 1973-29665-001; PMID 4715636]
73. Schooler 1993 {published data only} Schooler NR, Keith SJ, Severe JB, Matthews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome.. International congress on schizophrenia research 1993;9:260.
74. Shelton 1969 {published data only} Shelton WH, Bishop MP, Gallant DM. The Achilles reflex and antipsychotic drugs. Current Therapeutic Research Clinical and Experimental 1969;11(1):22-6. [MEDLINE: 69084988; : PMID 4973850]
75. Singh 1992 {published data only} Singh I, Owino WJE. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders.. Journal of Intellectual Disability Research 1992;36:541-9.
76. Svestka 1986 {published data only} Svestka J, Nahunek K, Ceskova E. Controlled cross-over comparison of oxyprothepine and clopenthixol decanoate in the prophylaxis of schizophrenic psychoses. Activitas Nervosa Superior 1986;28(1):35-6. [: PsycINFO 75-08452]
77. Syvalahti 1997 {published data only} Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, Dahl ML, Salokangas RK. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MEDLINE: 97179384; : PMID 9027670]
78. Taymeeyapradit 2002 {published data only} Taymeeyapradit U, Kuasirikul S. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand 2002;85(12):1301-8. [MEDLINE: 2003183416]
79. Tegeler 1985 {published data only} Tegeler J. A comparative trial of Cis(Z)-clopenthixol-decanoate and fluphenazine-decanoate. Pharmacopsychiatry 1985;18(1):78-9. [MEDLINE: 97179384; : PMID 9027670]
80. Uys 1996 {published data only} Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared to clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. Unpublished Report 1996. [MEDLINE: 74083340]
81. Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared with clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. 20th Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1996 Jun 23-27; Melbourne, Australia. 1996. [MEDLINE: 74083340; : PsycINFO 52-05954; PMID 4589640]
82. Venkateswarlu 1990 {published data only} Venkateswarlu T, Staley CJ, Neal CD. Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients:a dose-ranging study.. International Journal of Geriatric Psychiatry 1990;5:265.
83. Viala 1988 {published data only} Viala A, Ba B, Durand A, Gouezo F, Hou N, Jorgensen A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 1988; 94(3):293-7. [MEDLINE: 88190287; : PMID 2895936]
84. Walker 1983 {published data only} Walker CA. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out- patients. Pharmatherapeutica 1983;3(5): 289-93. [MEDLINE: 83195220; : PMID 6133287]
85. Weiser 1975 {published data only} Weiser G, Tahedl A, Reisecker F, Meyer H. Advantages of the initial therapy of acute schizophrenia with large doses of droperidol/A comparative study (author's transl) [Vorteile der Initialbehandlung akuter Schizophrenien mit hochdosiertem Droperidol. Eine Vergleichsstudie]. Arzneimittel Forschung 1975;25(11):1845-8. [MEDLINE: 76088237; : PMID 1243093]
86. Wistedt 1991 {published data only} Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Molbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatrica Scandinavica 1991;84(1):14-21. [MEDLINE: 92025271; : PMID 1681680]
87. Xiaanao 1999 {published data only} Xiaanoao G, Jiaju X, Mingshen W. Efficacy of clopenthixol in treating delusions and halucinations in schizophrenia. Journal of Clinical Psychology 1999;9(4):202-3.
88. Youssef 1991 {published data only} Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clinical Neuropharmacology 1991;14(suppl.2) :S16-S23.
89. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information.. BMJ 1996;313:1200.
90. Awad 1997 Awad GA, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11:32-47. 1997;11:32-47.
91. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
92. Chouinard 1980 Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Science 1980;7:233.
93. Coutinho 2004 Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. The Cochrane Library 2004, Issue 1.[Art. No.: CD001164. DOI: 10.1002/ 14651858.CD001164]
94. Dally 1967 Dally P. Chemotherapy of Psychiatric Disorders. London: Logos Press Limited, 1967.
95. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
96. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
97. Egger 1997 Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
98. Gibson 2004 Gibson R, Fenton M, Coutinho ESF, Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. The Cochrane Library 2004, Issue 1.
99. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of communitybased surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999; 149:876-83.
100. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
101. Higgins 2005 Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: Higgins JPT, Green S editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2005.
102. Jablensky 1992 Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization tencountry study. Psychological Medicine 1992;20(Monograph Supplement):1-97.
103. Kay 1987 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13: 261-76.
104. Kozyrev 2003 Kozyrev VN, Smulevich AB, Drobizhev MIu, Kraeva GK, Kubrakov MA. Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects).. Zh Nevrol Psikhiatr Im S S Korsakova 2003;103(11):25-32.
105. Lingjaerde 1987 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 1987;76(334):100.
106. Mace 2005 Mace S, Taylor D. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance.. International Journal of Psychiatry in Clinical Practice 2005;9(2): 124-9.
107. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
108. Moher 2001 Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191-4.
109. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389.
110. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
111. Percudani 2005 Percudani M. Barbui C. Fortino I. Petrovich L. Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy.. Pharmacopsychiatry 2005;38(3):128-31.
112. Taylor 2000 Taylor D, Kerwin R. Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol. Psychiatric Bulletin 2000;24:106-8.
113. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]